A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

NCT ID: NCT04161885

Last Updated: 2025-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

465 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-26

Study Completion Date

2025-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT).

This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the efficacy and safety of venetoclax with azacitidine (Part 2 Arm A) will be compared with BSC (Part 2 Arm B).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia (AML) Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care

Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)

Group Type EXPERIMENTAL

Venetoclax

Intervention Type DRUG

Tablet; Oral

Azacitidine

Intervention Type DRUG

Subcutaneous (SC) or intravenous (IV) injection

Best Supportive Care (BSC)

Intervention Type OTHER

BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC

Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).

Group Type EXPERIMENTAL

Venetoclax

Intervention Type DRUG

Tablet; Oral

Azacitidine

Intervention Type DRUG

Subcutaneous (SC) or intravenous (IV) injection

Best Supportive Care (BSC)

Intervention Type OTHER

BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

Part 2: Arm B - Best Supportive Care (BSC)

Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)

Group Type EXPERIMENTAL

Best Supportive Care (BSC)

Intervention Type OTHER

BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venetoclax

Tablet; Oral

Intervention Type DRUG

Azacitidine

Subcutaneous (SC) or intravenous (IV) injection

Intervention Type DRUG

Best Supportive Care (BSC)

BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-199 GDC-0199 VENCLEXTA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be at least 18 years old for Part 1 and, at least 12 years old for Part 2.
* Participant must be diagnosed with Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria (2017) and either be planning for allogeneic stem cell transplantation or have received allogeneic stem cell transplantation within the past 60 days.
* Blast percentage in bone marrow before transplant must be \< 10%.
* Blast count in peripheral blood must be "0" and Blast percentage in bone marrow must be \< 5% after transplant.
* Participant meet adequate renal, hepatic and hematologic criteria as described in the protocol.
* Participants \>= 17 years old must have a Karnofsky Performance Scale (KPS) score \> 50 and participants between 12 to 16 years old must have a Lansky Play Performance Scale score \> 40.

Exclusion Criteria

* History of disease progression during prior treatment with venetoclax.
* History of any other malignancy within 2 years prior to study entry, except for: Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; Myelodysplastic Syndrome, Myeloproliferative neoplasm (only allowed if it transformed to AML and AML should be the indication for marrow transplantation).
* Participant has known infection with HIV or history of being positive for hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
* Presence of clinical or laboratory symptoms/signs of extramedullary myeloid malignancy.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Oncology - Scottsdale - Cancer Transplant Institute /ID# 239711

Scottsdale, Arizona, United States

Site Status

University of Arizona Cancer Center - Tucson /ID# 242507

Tucson, Arizona, United States

Site Status

University of Arkansas for Medical Sciences /ID# 239804

Little Rock, Arkansas, United States

Site Status

City of Hope /ID# 213681

Duarte, California, United States

Site Status

UCHSC Anschultz Cancer Pavilion /ID# 215618

Aurora, Colorado, United States

Site Status

Colorado Blood Cancer Institute /ID# 215980

Denver, Colorado, United States

Site Status

Mayo Clinic /ID# 239710

Jacksonville, Florida, United States

Site Status

AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 213985

Orlando, Florida, United States

Site Status

Ann & Robert H Lurie Children's Hospital of Chicago /ID# 215840

Chicago, Illinois, United States

Site Status

The University of Chicago Medical Center /ID# 215616

Chicago, Illinois, United States

Site Status

Loyola University Medical Ctr /ID# 215617

Maywood, Illinois, United States

Site Status

Indiana Blood & Marrow Transpl /ID# 215842

Indianapolis, Indiana, United States

Site Status

Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 213834

New Orleans, Louisiana, United States

Site Status

University of Maryland, Baltimore /ID# 213855

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital /ID# 215765

Boston, Massachusetts, United States

Site Status

Karmanos Cancer Institute - Dresner Clinic /ID# 214581

Detroit, Michigan, United States

Site Status

Masonic Cancer Center /ID# 239492

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic - Rochester /ID# 214685

Rochester, Minnesota, United States

Site Status

University of Mississippi Medical Center /ID# 239343

Jackson, Mississippi, United States

Site Status

The John Theurer Cancer /ID# 215251

Hackensack, New Jersey, United States

Site Status

Roswell Park Cancer Institute /ID# 217857

Buffalo, New York, United States

Site Status

Columbia University Medical Center /ID# 240875

New York, New York, United States

Site Status

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 240680

New York, New York, United States

Site Status

Weill Cornell Medical College /ID# 214887

New York, New York, United States

Site Status

Montefiore Medical Center - Moses Campus /ID# 241669

The Bronx, New York, United States

Site Status

University of North Carolina /ID# 215814

Chapel Hill, North Carolina, United States

Site Status

Wake Forest Univ HS /ID# 239210

Winston-Salem, North Carolina, United States

Site Status

UC Health - Cincinnati /ID# 239263

Cincinnati, Ohio, United States

Site Status

University Hospitals - Seidman Cancer Center /ID# 239260

Cleveland, Ohio, United States

Site Status

University of Oklahoma, Stephenson Cancer Center /ID# 215611

Oklahoma City, Oklahoma, United States

Site Status

Oregon Health and Science University /ID# 215874

Portland, Oregon, United States

Site Status

Penn State Hershey Medical Ctr /ID# 217120

Hershey, Pennsylvania, United States

Site Status

Children's Hospital of Philadelphia - Main /ID# 215410

Philadelphia, Pennsylvania, United States

Site Status

Perelman Center for Advanced Medicine /ID# 214518

Philadelphia, Pennsylvania, United States

Site Status

Duplicate_Allegheny General Hospital /ID# 216756

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Hillman Cancer Ctr /ID# 213715

Pittsburgh, Pennsylvania, United States

Site Status

TriStar Centennial Medical Center /ID# 218750

Nashville, Tennessee, United States

Site Status

Texas Oncology - Medical City Dallas /ID# 216720

Dallas, Texas, United States

Site Status

Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 213735

Dallas, Texas, United States

Site Status

Texas Transplant Institute /ID# 214691

San Antonio, Texas, United States

Site Status

Virginia Commonwealth University Medical Center Main Hospital /ID# 239203

Richmond, Virginia, United States

Site Status

Fred Hutchinson Cancer Research Center /ID# 214436

Seattle, Washington, United States

Site Status

Univ of Wisconsin Hosp/Clinics /ID# 216096

Madison, Wisconsin, United States

Site Status

The Kinghorn Cancer Centre /ID# 214660

Darlinghurst, New South Wales, Australia

Site Status

Royal Adelaide Hospital /ID# 215678

Adelaide, South Australia, Australia

Site Status

Peter MacCallum Cancer Ctr /ID# 214653

Melbourne, Victoria, Australia

Site Status

The Alfred Hospital /ID# 240931

Melbourne, Victoria, Australia

Site Status

Hospital de Clinicas de Porto Alegre /ID# 215042

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Amaral Carvalho - Fundacao Doutor Amaral Carvalho /ID# 215145

Jaú, São Paulo, Brazil

Site Status

Hospital Nove de Julho /ID# 242359

São Paulo, São Paulo, Brazil

Site Status

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 239516

São Paulo, , Brazil

Site Status

Vancouver Coastal Health Research Institute (VCHRI) /ID# 215363

Vancouver, British Columbia, Canada

Site Status

University Health Network_Princess Margaret Cancer Centre /ID# 215344

Toronto, Ontario, Canada

Site Status

CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 214591

Montreal, Quebec, Canada

Site Status

Royal Victoria Hospital / McGill University Health Centre /ID# 215253

Montreal, Quebec, Canada

Site Status

Saskatoon Cancer Centre /ID# 238821

Saskatoon, Saskatchewan, Canada

Site Status

Peking University People's Hospital /ID# 215551

Beijing, Beijing Municipality, China

Site Status

Chinese PLA General Hospital /ID# 216287

Beijing, Beijing Municipality, China

Site Status

Aerospace Center Hospital /ID# 217018

Beijing, Beijing Municipality, China

Site Status

Fujian Medical University Union Hospital /ID# 215555

Fuzhou, Fujian, China

Site Status

Guangdong Provincial People's Hospital /ID# 218666

Guangzhou, Guangdong, China

Site Status

Zhujiang Hospital of Southern Medical University /ID# 216333

Guangzhou, Guangdong, China

Site Status

Nanfang Hospital of Southern Medical University /ID# 215553

Guangzhou, Guangdong, China

Site Status

Shenzhen Second People's Hospital /ID# 239401

Shenzhen, Guangdong, China

Site Status

Henan Cancer Hospital /ID# 215554

Zhengzhou, Henan, China

Site Status

Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 215552

Wuhan, Hubei, China

Site Status

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 238373

Wuhan, Hubei, China

Site Status

Xiangya Hospital Central South University /ID# 219025

Changsha, Hunan, China

Site Status

Zhongda Hospital Southeast University /ID# 218926

Nanjing, Jiangsu, China

Site Status

The First Affiliated Hospital of Soochow University /ID# 216605

Suzhou, Jiangsu, China

Site Status

The Affiliated Hospital of Xuzhou Medical College /ID# 239098

Xuzhou, Jiangsu, China

Site Status

The First Affiliated Hospital of Nanchang University /ID# 239168

Nanchang, Jiangxi, China

Site Status

Shanghai Changhai Hospital /ID# 216334

Shanghai, Shanghai Municipality, China

Site Status

Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 216282

Xi’an, Shanxi, China

Site Status

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215546

Tianjin, Tianjin Municipality, China

Site Status

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215550

Hangzhou, Zhejiang, China

Site Status

Fakultní Nemocnice Brno - Jihlavská /ID# 214811

Brno, Brno-mesto, Czechia

Site Status

Fakultní nemocnice Hradec Králové - Sokolská /ID# 214814

Hradec Králové, Hradec Kralove, Czechia

Site Status

Fakultni Nemocnice Ostrava /ID# 239922

Ostrava, Ostrava-mesto, Czechia

Site Status

Ustav hematologie a krevni transfuze /ID# 215133

Prague, , Czechia

Site Status

Duplicate_CHU de Nice - Hôpital Archet 1 /ID# 214056

Nice, Alpes-Maritimes, France

Site Status

CHU de Besancon - Jean Minjoz /ID# 241171

Besançon, Doubs, France

Site Status

Duplicate_CHU Bordeaux - Hopital Haut Leveque /ID# 214055

Pessac, Gironde, France

Site Status

CHRU Lille - Hopital Claude Huriez /ID# 217916

Lille, Nord, France

Site Status

CHU de Nantes, Hotel Dieu -HME /ID# 214060

Nantes, Pays de la Loire Region, France

Site Status

Hôpital Saint-Louis /ID# 214054

Paris, , France

Site Status

AP-HP - Hopital Saint-Antoine /ID# 216957

Paris, , France

Site Status

Hopital Pitie Salpetriere /ID# 241072

Paris, Île-de-France Region, France

Site Status

Universitaetsklinik Heidelberg /ID# 216623

Heidelberg, Baden-Wurttemberg, Germany

Site Status

Klinikum Augsburg /ID# 239583

Augsburg, Bavaria, Germany

Site Status

Universitaetsklinikum Wuerzburg /ID# 215212

Würzburg, Bavaria, Germany

Site Status

Universitaetsklinikum Muenster /ID# 215213

Münster, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum Carl Gustav Carus Dresden /ID# 214244

Dresden, Saxony, Germany

Site Status

Universitaetsklinikum Leipzig /ID# 245892

Leipzig, Saxony, Germany

Site Status

Universitaetsklinikum Halle (Saale) /ID# 239585

Halle, , Germany

Site Status

Medizinische Hochschule Hannover /ID# 214243

Hanover, , Germany

Site Status

General Hospital of Athens Evangelismos /ID# 238810

Athens, Attica, Greece

Site Status

University General Hospital Attikon /ID# 238812

Athens, Attica, Greece

Site Status

University General Hospital of Patras /ID# 238811

RION Patras Achaia, , Greece

Site Status

Debreceni Egyetem-Klinikai Kozpont /ID# 241123

Debrecen, Hajdú-Bihar, Hungary

Site Status

Schneider Children's Medical Center /ID# 224326

Petah Tikva, Central District, Israel

Site Status

Rambam Health Care Campus /ID# 214507

Haifa, H_efa, Israel

Site Status

Hadassah Medical Center-Hebrew University /ID# 218697

Jerusalem, Jerusalem, Israel

Site Status

Sheba Medical Center /ID# 239571

Ramat Gan, Tel Aviv, Israel

Site Status

The Chaim Sheba Medical Center /ID# 214305

Ramat Gan, Tel Aviv, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 214508

Tel Aviv, Tel Aviv, Israel

Site Status

Rabin Medical Center /ID# 214509

Petah Tikva, , Israel

Site Status

IRCCS Ospedale San Raffaele /ID# 214311

Milan, Milano, Italy

Site Status

Istituto Europeo Di Oncologia /ID# 242579

Milan, Milano, Italy

Site Status

A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 216148

Turin, Piedmont, Italy

Site Status

Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 254964

Rome, Roma, Italy

Site Status

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 214910

Rome, Roma, Italy

Site Status

ASST degli Spedali Civili di Brescia /ID# 215997

Brescia, , Italy

Site Status

Anjou Kousei Hospital /ID# 215857

Anjo-shi, Aichi-ken, Japan

Site Status

Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 215679

Nagoya, Aichi-ken, Japan

Site Status

University of Fukui Hospital /ID# 253383

Yoshida-gun, Fukui, Japan

Site Status

Kyushu University Hospital /ID# 215285

Fukuoka, Fukuoka, Japan

Site Status

Fukushima Medical University Hospital /ID# 252293

Fukushima, Fukushima, Japan

Site Status

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 217522

Hiroshima, Hiroshima, Japan

Site Status

Hokkaido University Hospital /ID# 215937

Sapporo, Hokkaido, Japan

Site Status

Kobe City Medical Center General Hospital /ID# 215388

Kobe, Hyōgo, Japan

Site Status

Hyogo Medical University Hospital /ID# 215389

Nishinomiya-shi, Hyōgo, Japan

Site Status

Kanazawa University Hospital /ID# 242955

Kanazawa, Ishikawa-ken, Japan

Site Status

Imamura General Hospital /ID# 215688

Kagoshima, Kagoshima-ken, Japan

Site Status

Tokai University Hospital /ID# 250086

Isehara, Kanagawa, Japan

Site Status

Kanagawa Cancer Center /ID# 215029

Yokohama, Kanagawa, Japan

Site Status

Kyoto University Hospital /ID# 243209

Kyoto, Kyoto, Japan

Site Status

Tohoku University Hospital /ID# 214670

Sendai, Miyagi, Japan

Site Status

Okayama University Hospital /ID# 214842

Okayama, Okayama-ken, Japan

Site Status

Osaka Metropolitan University Hospital /ID# 215227

Osaka, Osaka, Japan

Site Status

Kindai University Hospital /ID# 214917

Osakasayama-shi, Osaka, Japan

Site Status

Jichi Medical University Saitama Medical Center /ID# 216092

Saitama-shi, Saitama, Japan

Site Status

Jichi Medical University Hospital /ID# 216091

Shimotsuke-shi, Tochigi, Japan

Site Status

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital /ID# 215939

Bunkyo-ku, Tokyo, Japan

Site Status

National Cancer Center Hospital /ID# 242639

Chuo-ku, Tokyo, Japan

Site Status

Toranomon Hospital /ID# 215311

Minato-ku, Tokyo, Japan

Site Status

National Center for Child Health and Development /ID# 242479

Setagaya-ku, Tokyo, Japan

Site Status

Keio University Hospital /ID# 243549

Shinjuku-ku, Tokyo, Japan

Site Status

Yamagata University Hospital /ID# 253304

Yamagata, Yamagata, Japan

Site Status

Seoul National University Hospital /ID# 214891

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Asan Medical Center /ID# 214893

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Samsung Medical Center /ID# 239087

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214892

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Hospital Clinic de Barcelona /ID# 215108

Barcelona, , Spain

Site Status

Hospital Santa Creu i Sant Pau /ID# 240397

Barcelona, , Spain

Site Status

Hospital General Universitario Gregorio Maranon /ID# 215107

Madrid, , Spain

Site Status

Hospital Universitario Ramon y Cajal /ID# 218102

Madrid, , Spain

Site Status

Hospital Universitario La Paz /ID# 218103

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocio /ID# 215463

Seville, , Spain

Site Status

Hospital Clinico Universitario de Valencia /ID# 215106

Valencia, , Spain

Site Status

Duplicate_Universitätsspital Basel /ID# 215892

Basel, Canton of Basel-City, Switzerland

Site Status

University Hospital Zurich /ID# 215891

Zurich, Canton of Zurich, Switzerland

Site Status

National Taiwan University Hospital /ID# 215245

Taipei City, Taipei, Taiwan

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 215197

Kaohsiung City, , Taiwan

Site Status

China Medical University Hospital /ID# 215198

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital /ID# 239288

Taichung, , Taiwan

Site Status

Taipei Veterans General Hosp /ID# 239289

Taipei, , Taiwan

Site Status

Linkou Chang Gung Memorial Hospital /ID# 215319

Taoyuan, , Taiwan

Site Status

Hammersmith Hospital /ID# 215665

London, England, United Kingdom

Site Status

Gartnavel General Hospital /ID# 215663

Glasgow, Glasgow City, United Kingdom

Site Status

University College London Hospital /ID# 215662

London, Greater London, United Kingdom

Site Status

University Hospitals Birmingham NHS Foundation Trust /ID# 215120

Birmingham, , United Kingdom

Site Status

King's College Hospital NHS Foundation Trust /ID# 215338

London, , United Kingdom

Site Status

The Royal Marsden NHS Foundation Trust /ID# 215124

London, , United Kingdom

Site Status

The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 248359

Newcastle upon Tyne, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Canada China Czechia France Germany Greece Hungary Israel Italy Japan South Korea Spain Switzerland Taiwan United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-507222-17-00

Identifier Type: OTHER

Identifier Source: secondary_id

M19-063

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
NCT06598384 NOT_YET_RECRUITING PHASE2